Clene Reveals Breakthrough ALS Trial Results and Extended Survival Data
Company Announcements

Clene Reveals Breakthrough ALS Trial Results and Extended Survival Data

Clene (CLNN) just unveiled an update.

Clene Inc. made a significant announcement on June 17, 2024, at the ENCALS Meeting, presenting promising clinical results of their CNM-Au8® treatment in an ongoing ALS trial. The next day, the company further publicized the extended survival data and new findings regarding neurofilament light responder results from the same trial, reinforcing the potential impact of their treatment on ALS patients, and sparking interest among investors and the wider public eyeing advancements in medical treatments.

For an in-depth examination of CLNN stock, go to TipRanks’ Stock Analysis page.

Related Articles
Austin AngeloCLNN Upcoming Earnings Report: What to Expect?
TipRanks Auto-Generated NewsdeskClene Unveils Phase 3 Trial Design at NEALS
TheFlyClene price target lowered to $86 from $94 at Canaccord
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App